CDE Announces 90th Batch of Reference Preparations for GQCE
China’s Center for Drug Evaluation (CDE) has selected the 90th batch of reference preparations for...
Fineline Cube
Solasia Pharma Licenses Episil to GeneScience for Greater China Region
Japan-based Solasia Pharma K. K (TYO: 4597) has announced a licensing agreement with Changchun GeneScience...
Alebund Pharmaceuticals Completes Series C Financing to Advance Kidney Disease Pipelines
Shanghai-based Alebund Pharmaceuticals has announced the completion of a Series C financing round, raising RMB...
GSK’s Nucala Receives New Indication Approval in China for CRSwNP
UK-based pharmaceutical company GlaxoSmithKline’s (GSK; NYSE: GSK) has announced that it has received another indication...
China’s Healthcare Bureaus Remove Drug Quantity Limits to Enhance NRDL Access
The healthcare security administration bureaus in Shanghai, Beijing, and other regions have recently removed limits...
Kexing Pharmaceutical Partners with Shandong Boan for Biosimilar Commercialization in Hong Kong and Macau
China-based Kexing Pharmaceutical (SHA: 688136) has entered into a commercialization cooperation agreement with fellow Chinese...
Shengwei Kunteng Raises RMB 200 Million in Series A Financing for POCT Development
China-based Hunan Shengwei Kunteng Biotechnology Co., Ltd has announced that it has raised close to...
Hangzhou Highlightll Pharma Completes Pre-Series C Financing Round
China-based Hangzhou Highlightll Pharmaceutical Co., Ltd has announced the successful completion of a Pre-Series C...
Aosaikang’s Generic Livtencity Accepted for Review by China’s NMPA
China’s Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has revealed that a market filing for...
Sinobioway Medicine Partners with Happy Life Tech for Clinical Trial Services
China-based Contract Manufacturing Organization (CMO) Sinobioway Medicine (SHE: 002581) has announced a clinical trial technical...
Balance Medtech’s Interventional Pulmonary Valve Receives Fast-Track Designation from NMPA
China’s Beijing Balance Medical Technology Co., Ltd. (SHA: 688198) has announced that it has received...
MicuRx Pharmaceuticals’ MRX-5 Receives NMPA Approval for NTM Infections Clinical Study
Sino-US firm MicuRx Pharmaceuticals Inc. (SHA: 688373) has announced that it has received approval from...
Huahai Pharmaceutical’s HB0028 and HB002.1T Cleared for Clinical Study by NMPA
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced that it has received clearance...
Hengrui Pharmaceuticals Receives NMPA Approval for HRS-6768 Clinical Trial
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has received clinical...
China’s State Council Aims to Enhance Drug and Medical Device Regulation by 2027
China’s State Council has released the “Opinions on Fully Deepening the Reform of Drug and...
Milestone Biotechnologies Secures Nearly 100 Million Yuan in Series A+ Funding
Milestone Biotechnologies, a leading biotechnology company based in Shanghai, has announced the completion of a...
AstraZeneca’s Tagrisso Receives NMPA Approval for EGFR-Mutated NSCLC Treatment
UK-based AstraZeneca (AZ, NASDAQ: AZN) has announced that it has received a new indication approval...
NMPA Approves Lynparza as Adjuvant Treatment for High-Risk Breast Cancer Patients
The National Medical Products Administration (NMPA) in China has granted AstraZeneca (AZ, NASDAQ: AZN) and...
Gilead Sciences’ Sunlenca Receives NMPA Approval for Multidrug-Resistant HIV-1 Infection
US-based pharmaceutical company Gilead Sciences Inc., (NASDAQ: GILD), has announced that it has received marketing...
WinHealth Pharma’s Difelikefalin Receives NMPA Review for Market Approval
China-based Hong Kong WinHealth Pharma Group has announced that the National Medical Products Administration (NMPA)...